



Salih Sanlioglu, V.M.D, Ph.D.

[Human Gene and Cell Therapy Center, Akdeniz University Hospitals and Clinics,](#)

B Block, 1st floor, Campus, Antalya, 07058, Turkiye

Work: 90 (242) 249-6157/ 249-6166

sanlioglu@akdeniz.edu.tr, ssanlioglu@me.com

<http://www.salihsanlioglu.com> ; <http://www.tsgct.org>



PROFESSIONAL EXPERIENCE:

2010- Professor, [Human Gene and Cell Therapy Center](#) of Akdeniz University,; Topic of interest: Gene Therapy of Diabetes and Cancer.

2008- Present Professor, [Department of Medical Biology and Genetics](#), Akdeniz University, College of Medicine; Topic of interest: Personalized Medicine.

2009- 2011 Professor, and the Chair (2010-2011) of [the Department of Medical Genetics](#), Akdeniz University, College of Medicine; Topic of interest: Personalized Medicine and Gene Therapy.

2002- 2010 Director of the [Human Gene Therapy Unit of Akdeniz University, Faculty of Medicine](#); Topic of interest: Development of novel gene therapy approaches against acquired human diseases such as cancer (prostate, lung, breast etc), diabetes and rheumatoid arthritis etc.

2002-2007 Associate Professor, Department of Medical Biology and Genetics, Akdeniz University, College of Medicine; Topic of interest: Molecular diagnostics.

2001-2002 Assistant Professor, Department of Medical Biology and Genetics, Akdeniz University, College of Medicine and [The Gene Therapy Center](#), Department of Internal Medicine, University of Iowa; Topic of interest: Adenovirus mediated gene therapy approach for sepsis.

1998- 2001 Research Fellow, [Gene Therapy Center](#) and [Department of Internal Medicine](#), College of Medicine, University of Iowa; Topic of interest: Molecular mechanism of AAV transduction and implications for human gene therapy.

1997-1998 Postdoctoral Associate, [Institute for Human Gene Therapy, College of Medicine; University of Pennsylvania](#) Topic of interest: AAV mediated gene therapy for liver.

1992-1996 Graduate Teaching and Research Associate, [College of Medicine, Ohio State University](#); Topic of interest: In vivo gene transfer and the disruption of cerebellar patterning.

1990-1992 National Scholar, [Children's Hospital, Ohio State University](#). Topic of interest:
Molecular cloning and characterization of two novel human genes.

1988-1990 Veterinary Medical Doctor (V.M.D.), [Faculty of Veterinary Medicine](#),
University of Selcuk.





EDUCATION:

- 1992-1996 Ph.D. Graduate Studies in [Molecular, Cellular Biology](#) and [Molecular Genetics](#), College of Medicine, the Ohio State University Supervisor: [John D. Oberdick](#). Thesis Title: [Ectopic Engrailed-2 expression through in vivo gene transfer and its consequence on cerebellar patterning. Journal of Neuroscience 18\(5\): 1763-73 1998.](#)
- 1990-1992 M.S. Graduate Studies in [Molecular, Cellular Biology](#) and [Molecular Genetics](#), College of Medicine, Ohio State University Supervisor: [Chack-Yung Yu](#). Thesis Title: [Molecular cloning and characterization of two novel human genes \(RP1 and RP2\) located upstream of complement C4A and C4B in the HLA Class III region. Journal of Biological Chemistry 269\(11\):8466-76, 1994.](#)
- 1988-1990 Graduate Studies in Microbiology and Immune-Serology at the Institute of Health, University of Selcuk.
- 1983-1988 Veterinary Medical Doctor (V.M.D), [Faculty of Veterinary Medicine](#), University of Selcuk



PUBLICATIONS (All ISI Indexed):

1. Tracing of xenogeneic islet graft survival by way of in vivo fluorescence imaging.
Kahraman S, Dirice E, Hapil FZ, Ertosun MG, Ozturk S, Griffith TS, Sanlioglu S and Sanlioglu AD. *Diabetes Metab Res Rev* 2011 27(6):575-83.
2. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Yoldas B, Ozer C, Ozen O, Canpolat T, Dogan I, Griffith TS, Sanlioglu S, Ozluoglu LN. *Head Neck*. 2011 33(9):1278-84.
3. NF-kappaB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. Aydin C, Sanlioglu AD, Bisgin A, Yoldas B, Dertsiz L, Karacay B, Griffith TS and Sanlioglu S. *BMC Cancer*. 2010, 10:584
4. TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8+ T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis. Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bageci H,

Gorczyński RM, Akdis CA, Sanlioglu S. BMC Musculoskelet Disord. 2010 Aug 27;11:192.

5. Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer. Koksall IT, Sanlioglu AD, Kutlu O, Sanlioglu S. Urol Int. 2010;84(4):445-51.
6. Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis. Kutlu O, Akkaya E, Koksall IT, Bassorgun IC, Ciftcioglu MA, Sanlioglu S, Kukul E. Int Urol Nephrol. 2010 Jun;42(2):393-9.
7. In Vivo Fluorescence Imaging is Well-Suited for the Monitoring of Adenovirus Directed Transgene Expression in Living Organisms. Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Bagci H, Erkilic M, Griffith TS and Sanlioglu S. Molecular Imaging and Biology. 2010 Jun; 12 (3):278-85.
8. Adenovirus mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Ozturk S, Balci MK, Omer A, Griffith TS and Sanlioglu S. Human Gene Therapy. Oct 2009, 20(10): 1177-1189

9. CTLA-4 gene polymorphism of exon I(+49 A/G) in Turkish systemic lupus erythematosus patients. Ulker M, Yazisiz V, Sallakci N, Avcı AB, Sanlioglu S, Yegin O, Terzioglu E. *Int J Immunogenet.* 2009 Aug;36(4):245-50
10. High TRAIL Death Receptor-4 (DR4) and Decoy Receptor-2 (DcR2) expression correlates with significant cell death in pancreatic ductal adenocarcinoma (PDAC) patients. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS and Sanlioglu S. *Pancreas* 2009 Mar;38(2):154-60.
11. Radiotherapy-induced decreases in substance P levels may potentiate melanoma growth. Korcum AF, Sanlioglu S, Aksu G, Tuncel N, Erin N. *Molecular Medicine Reports* 2009 Mar-Apr; 2(2): 319-326.
12. Molecular mechanisms of death ligand-mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes. Sanlioglu AD, Griffith TS, Omer A, Dirice E, Sari R, Altunbas HA, Balci MK, and Sanlioglu S. *J Cell Biochem* 2008 June 1; 104(3):710-720.
13. High levels of endogenous TRAIL expression correlate with increased cell death in human pancreas. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS and Sanlioglu S. *Pancreas* 2008 May; 36(4):385-393.

14. TRAIL-R4 decoy receptor gene expression is correlated with high Gleason scores, PSA recurrence and decreased survival in patients with prostate carcinoma. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS and Sanlioglu S. *Urologic Oncology* 2008 Mar-Apr; 26(2):158-165.
15. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS and Sanlioglu S. *Cancer Gene Therapy*. 2007 Dec; 14(12):976-984.
16. Corneal protein nitration in experimental uveitis. Aslan M, Yucel I, Akar Y, Yücel G, Ciftcioglu MA and Sanlioglu S. *Exp Biol Med (Maywood)*. 2007 Nov; 232(10):1308-1313.
17. TRAIL death receptor-4 (DR4) expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S. *Int J Radiat Oncol Biol Phys*. 2007 Nov; 69(3): 716-723.
18. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Terzioglu E, Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner

- S, and Sanlioglu S. *Rheumatology (Oxford)*. 2007 May; 46(5): 783-789.
19. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. *Human Gene Therapy*. 2007 Jan; 18: 39-50.
20. Dajani R, Sanlioglu S, Zhang Y, Li Q, Monick MM, Lazartigues E, Eggleston T, Davisson RL, Hunninghake GH, Engelhardt JF. Pleiotropic Functions of TNF alpha Determine Distinct IKK beta-Dependent Hepatocellular Fates in Response to LPS. *Am J Physiol Gastrointest Liver Physiol*. 2007 Jan; 292(1): G242-252.
21. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. Sanlioglu AD, Koksai IT, Ciftcioglu MA, Baykara M, Luleci G and Sanlioglu S. *Journal of Urology*. 2007 Jan; 177(1): 359-364.
22. Nitrotyrosine Formation and Apoptosis in Rat Models of Ocular Injury. Aslan M, Yucel I, Akar Y, Yucel G, Ciftcioglu MA and Sanlioglu S. *Free Radical Research*. 2006 Feb; 40(2): 147-153.

23. Adenovirus mediated IKK β KA expression sensitizes prostate carcinoma cells to TRAIL induced apoptosis. Sanlioglu AD, Koksall IT, Karacay B, Baykara M, Luleci G and Sanlioglu S. *Cancer Gene Therapy*. 2006 Jan; 13(1): 21-31
24. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. *BMC Cancer*. 2005 25;5(1):54
25. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Koksall IT, Yasar D, Dirice E., Usta MF, Karauzum S, Luleci G, Baykara M and Sanlioglu S. *Urol Int*. 2005 75(2): 102-106
26. The effect of cetirizine on IFN - γ ve IL - 10 production in children with allergic rhinitis. Uguz A, Sanlioglu S, Yuzbey S, Coskun M, Yegin O. *Turkish Journal of Pediatrics*. 2005 47: 111-115
27. Inhibition of the NF- κ B Pathway Enhances TRAIL-Mediated Apoptosis in Neuroblastoma Cells. Karacay B, Sanlioglu S, Griffith TS, Sandler A and Bonthius DJ. *Cancer Gene Therapy*. 2004 Oct; 11(10): 681-690.

28. Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Sanlioglu AD, Karacay B, Benson PK, Engelhardt JF and Sanlioglu S. *Virus Research*. 2004 Aug; 104(1): 51-59.
29. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Koksal IT, Dirice E, Yasar D, Sanlioglu AD, Gulkesen KH, Ciftcioglu A., Ozes ON, Baykara M, Luleci G and Sanlioglu S. *Urol Oncol*. 2004 22(4): 307-312.
30. Fundamental Principles of Tumor Necrosis Factor-alpha gene therapy approach and implications for patients with lung carcinoma. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E and Sanlioglu S. *Lung Cancer*. 2004 44: 199-211.
31. Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma. Sanlioglu AD, Koksal T, Baykara M, Luleci G, Karacay B, Sanlioglu S. *Gene Ther Mol Biol*. 2003 7: 113-133.
32. Genetic redox preconditioning differentially modulates AP-1 and NFkappaB responses following cardiac ischemia/reperfusion injury and protects against necrosis and apoptosis. Yang J, Marden JJ, Fan C, Sanlioglu S, Weiss RM, Ritchie TC, Davisson RL, Engelhardt JF. *Molecular Therapy*. 2003 Mar;7(3): 341-353

33. First generation adenovirus vectors shorten survival time in a murine model of sepsis. Sanlioglu, S, Doerschug K, Flaherty, DM, Wilson RL, Yarovinsky TO, Monick MM, Engelhardt JF and Hunninghake GW. *J. Immunology*. 2002 169: 6539-6545.
34. Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant-dependent mechanism. Samavati L, Monick MM, Sanlioglu S, Buettner GR, Oberley LW, and Hunninghake GW. *Am J Physiol Cell Physiol*. 2002 Jul;283(1): C273-81.
35. Simultaneous inhibition of Rac1 and IKK Pathways sensitizes lung cancer cells to TNF α mediated apoptosis. Sanlioglu S, Luleci G and Thomas KW. *Cancer Gene Therapy*. 2001 8(11): 897-905.
36. GPx-1 gene delivery modulates NF κ B activation following diverse environmental injuries through a specific subunit of the IKK complex. Li Q, Sanlioglu S, Li S, Ritchie T, Oberley L and Engelhardt JF. *Antioxidant and Redox Signaling*. 2001 3(3): 415-431.
37. LPS induces Rac1 dependent reactive oxygen species (ROS) formation and coordinates TNF α secretion through IKK regulation of NF κ B. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB, Ritchie TC, Hunninghake GW, Zandi E and Engelhardt JF. *JBC*. 2001 Aug 276(32): 30188-30198.

38. Rate Limiting Steps of AAV transduction and Implications for Human Gene Therapy.
Sanlioglu S, Monick MM, Luleci G, Hunninghake GW and Engelhardt JF. Review.
Current Gene Therapy. 2001 June; 1(2): 137-147.
39. Endocytosis and Nuclear Trafficking of Adeno-Associated Virus Type-2 is
Controlled by Rac1/PI3-kinase Activation. Sanlioglu S, Benson PK, Yang J,
Atkinson EM, Reynolds T and Engelhardt JF. Journal of Virology. 2000 Oct;
74(19): 9184-9196 (Cover illustration)
40. Loss of ATM Function Enhances Recombinant Adeno-Associated Virus
Transduction and Integration through Pathways Similar to UV Irradiation. Sanlioglu S,
Benson P, Engelhardt JF. Virology. 2000 Mar 1; 268(1): 68-78 (Cover illustration)
41. Two Independent Molecular Pathways for Recombinant Adeno-Associated virus
genome conversion occur after UV-C and E4orf6 augmentation of transduction.
Sanlioglu S, Duan D and Engelhardt JF. Human Gene Therapy. 1999 March 1; 10(4):
591-602.
42. Cellular Redox State Alters Recombinant Adeno-Associated Virus Transduction
Through Tyrosine Phosphatase Pathways. Sanlioglu S and Engelhardt JF. Gene
Therapy. 1999 6: 1427-1437.

43. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4-ORF6 and E2a gene expression. Duan D, Sharma P, Dudas L, Zhang Y, Sanlioglu S, Yan Z, Yue Y, Lester R, Yang J, Fisher KJ, Engelhardt, J.F. *Journal of Virology*. 1999 73(1): 161-169.
44. Selective disruption of "late onset" sagittal banding patterns by ectopic expression of engrailed-2 in cerebellar Purkinje cells. Baader SL, Vogel MW, Sanlioglu S, Zhang X, Oberdick J. *Journal of Neuroscience*. 1999 Jul 1; 19(13): 5370-5379.
45. Regulation of a Purkinje cell-specific promoter by homeodomain proteins: repression by engrailed-2 vs. synergistic activation by Hoxa5 and Hoxb7. Sanlioglu S, Zhang X, Baader SL, Oberdick J. *Journal of Neurobiology*. 1998 Sep 15; 36(4): 559-571.
46. Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions. Sanlioglu S, Baader SL, Berrebi AS, Parker-Thornburg J, Oberdick J. *Journal of Neuroscience*. 1998 Mar 1; 18(5): 1763-1773.

47. Functional cloning of candidate genes that regulate Purkinje cell-specific gene expression. Sanlioglu-Crisman S. and Oberdick J. *Progress in Brain Research*. 1997 114: 3-19.
48. Local control of granule cell generation by cerebellar Purkinje cells. Smeyne R, Chu T, Lewin A, Bian F, Sanlioglu-Crisman S, Kunsch C, Lira SA and Oberdick J. *Mol Cell Neuroscience*. 1995 6: 230-251.
49. Structure and genetics of the partially duplicated gene *RP* located immediately upstream of the complement *C4A* and *C4B* genes in the HLA class III region. Shen L, Wu LC, Sanlioglu S, Chen R, Mendoza AR, Dangel A, Carroll MC, Zipf WB, Yung CY. *Journal of Biological Chemistry*. 1994 269(11): 8466-8476.
50. Isolation of *Acinetobacter lwoffii* from hens with septicemia Kaya O, Ates M, Erganis O, Corlu M. and Sanlioglu S. *Journal of Veterinary Medicine*. 1989 36(2): 157-158.



ABSTRACTS and PRESENTATIONS (INTERNATIONAL MEETINGS):

1. A novel combinatorial gene therapy modality successfully destroyed synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Yazisiz V, et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X61. Clinical Genetics Volume: 78 issue Supplements 1. Page: 128.
2. Efficacy of clinical gene and cell therapy in ADA SCID patients. Bisgin A and Sanlioglu S. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X62. Clinical Genetics Volume: 78 issue Supplements 1. Page: 128.
3. In vivo tracing of the most commonly used gene therapy vector. Kahraman S, Dirice E, Sanlioglu AD et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X63. Clinical Genetics Volume: 78 issue Supplements 1. Page: 128.

4. In vivo fluorescence tracing of xenogeneic islet graft survival in Type I Diabetes.
Kahraman S, Dirice E, Hapil FZ et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract X64. Clinical Genetics Volume: 78 issue Supplements 1. Page: 129.
5. Clinical genetic significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Yoldas B, Ozer C, Ozen O et al. 9th National Medical Genetics Congress, 1-5 December 2010, Istanbul, Turkey. Abstract H07. Clinical Genetics Volume: 78 issue Supplements 1. Page: 59.
6. Spontaneous type I diabetes in NOD mice is related to an increase in DcR1 expression. Kahraman S, Dirice E, Elpek O, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY.
HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1447-1448
Published: OCT 2010
7. Trail profile of synoviocytes and peripheral blood lymphocytes of rheumatoid arthritis patients. Bisgin A, Sanlioglu AD, Yoldas B, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY.
HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1448-1449
Published: OCT 2010

8. In vivo fluorescence imaging of xenogeneic islet graft survival. Kahraman S, Dirice E, Hapil FZ, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1451-1451 Published: OCT 2010

9. STZ administration leads to a significant rise in TRAIL and DcR1 levels in Non-Obese Diabetic (NOD). 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1453-1453 Published: OCT 2010

10. TRAIL expression significantly decreases in CY-accelerated type 1 diabetes in NOD mice. Kahraman S, Dirice E, Elpek O, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1453-1454 Published: OCT 2010

11. The importance of sTRAIL in patients with rheumatoid arthritis. Bisgin A, Terzioglu E, Erbasan F, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1461-1461 Published: OCT 2010

12. The outcome of trail presentation on T cells in patients with multiple myeloma. Hapil FZ, Bisgin A, Aydin C, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1462-1462 Published: OCT 2010

13. Distinctive expression profiles of trail and trail receptors in patients with endometrial carcinoma. Aydin C, Bisgin A, Sanlioglu AD, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1462-1462 Published: OCT 2010

14. Endometrial hyperplasia features distinctive trail and trail receptor expression profiles. Aydin C, Bisgin A, Sanlioglu AD, et al. 18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, OCT 22-25, 2010 Milan, ITALY. HUMAN GENE THERAPY Volume: 21 Issue: 10 Pages: 1462-1463 Published: OCT 2010

15. Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. Bisgin A, Kargi A, Yalcin A, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV

21-25, 2009 Hannover, GERMANY. HUMAN GENE THERAPY Volume: 20

Issue: 11 Pages: 1417-1417 Published: NOV 2009

16. Distinctive expression profile of TRAIL and TRAIL receptors in patients with head and neck cancer. Yoldas B, Ozer C, Ozen O, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1422-1423 Published: NOV 2009

17. TRAIL death receptor-4 and decoy receptors expression on CD8+T cells correlate with the disease severity in rheumatoid arthritis patients. Bisgin A, Terzioglu E, Aydin C, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY. HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1471-1471 Published: NOV 2009

18. Adenovirus mediated TRAIL gene therapy approach provides sustained insulin expression in STZ-induced diabetic rats. Dirice E, Sanlioglu A, Kahraman S, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research,

NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume:
20 Issue: 11 Pages: 1471-1472 Published: NOV 2009

19. In vivo fluorescence imaging as a method to assess pancreatic islet xenograft failure. Kahraman S, Hapil FZ, Ertosun MG, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1479-1479 Published: NOV 2009

20. Tracing of the fate of allogeneic islet grafts via CCD camera. Kahraman S, Hapil FZ, Aydin C, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1479-1479 Published: NOV 2009

21. Prospective cell and gene therapy approaches designed to extend islet graft survival in patients with type 1 diabetes. Sanlioglu S Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1482-1483 Published: NOV 2009

22. Alterations in TRAIL ligand and receptor expression profiles in CY-accelerated type 1 diabetes in NOD mice. Sanlioglu A, Kahraman S, Dirice E, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1483-1483 Published: NOV 2009

23. Differential levels of TRAIL ligand and receptor expressions in STZ-induced T1 diabetes in non-obese diabetic (NOD) mice. Sanlioglu AD, Dirice E, Kahraman S, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1483-1483 Published: NOV 2009

24. Diagnostic significance of serum sTRAIL in rheumatoid arthritis. Bisgin A, Aydin C, Erbasan F, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1494-1494 Published: NOV 2009

25. Monitoring of systemic delivery of adenovirus mediated EGFP transgene expression in mice using fluorescence imaging. Kahraman S, Dirice E, Sanlioglu A, et al. Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, NOV 21-25, 2009 Hannover, GERMANY, HUMAN GENE THERAPY Volume: 20 Issue: 11 Pages: 1507-1507 Published: NOV 2009

26. A novel gene therapy strategy involving immune-modulation relinquished lymphocyte infiltration into islet grafted sites in STZ induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstract. OC2.1. 11th European Congress of Endocrinology. 25-29 April 2009, Istanbul, Turkey.

27. Comparative molecular analysis of TRAIL ligand and receptor expression profiles in cyclophosphamide versus streptozotocin-induced diabetes in non-obese diabetic (NOD) mice. Kahraman S, Dirice E, Elpek O, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. Abstract. P336. 11th European Congress of Endocrinology. 25-29 April 2009, Istanbul, Turkey.

28. Cell and gene therapy approaches to prolong islet-graft survival in patients with type 1 diabetes. Dirice E, Sanlioglu AD, Kahraman S, Balci MK, Omer A and Sanlioglu S.

Abstract. S13-6. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 314.

29. Genetically engineered pancreatic islets expressing TRAIL extends survival of transplanted pancreatic islets in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK and Sanlioglu S. Abstract. P-60. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 341.

30. In vivo fluorescent imaging of allogeneic and xenogeneic islet grafts following transplantation. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A and Sanlioglu S. Abstract. P-196. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 378-379.

31. Highlights in the molecular pathogenesis of type I diabetes. Kahraman S, Dirice E, Elpek O, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. Abstract. P-04. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 324-325.

32. Molecular characterization of TRAIL ligand and receptor expressions in cyclophosphamide-induced type I diabetes in NOD mice. Dirice E, Kahraman S, Balci MK, Omer A, Sanlioglu S, and Sanlioglu AD. Abstract. P-04. 3rd International

Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 324-325.

33. Molecular profile of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors on T cells in patients with Rheumatoid Arthritis. Bisgin A, Yazisiz V, Terzioglu E, et al. Abstract. P-04. 3rd International Congress of Molecular Medicine, 5-8 May 2009, Istanbul, Turkey. IUBMB Life, 61 (3); 327.

34. The potential use of TRAIL and its receptor expression profile as markers to monitor the prognosis of patients with rheumatoid arthritis. Bisgin A, Terzioglu E, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA and Sanlioglu S. Abstract. P104. World Immune Regulation Meeting-III. 22-25 March 2009, Davos, Switzerland.

35. Serum s TRAIL us efor the assessment of the efficacy of BevacizumAb treatment in metastatic colon cancer. Bisgin A, Kargı A, Yalcin AD, Aydin C, Ekinci D, Terzioglu E, Savas B and Sanlioglu S. Abstract. P-08. JOINT 4th EORTC Pathobiology Group Annual Meeting and 1st International Multidisciplinary Cancer Research Congress. 21-24 May 2009, Antalya, Turkey.

36. CD8⁺ T cell associated TRAIL DR4 death and DcR1, DcR2 decoy receptors expression correlate with disease severity in patients with rheumatoid arthritis. Bisgin

A, Terzioglu E, Aydin C, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA and Sanlioglu S. Abstract. FRI-0065. 10-13 June 2009, Copenhagen, Denmark.

37. Rheumatoid arthritis disease activity is correlated with TRAIL death receptor-4 and decoy receptors expression on CD8+ T cells. Bisgin A, Terzioglu E, Aydin C, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA and Sanlioglu S. Abstract. P6-2. 34th FEBS Congress. 4-9 July 2009, Prague, Czech Republic.

38. Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer. Bisgin A, Aydin C, Terzioglu E, Yalcin AD, Kargi A, Savas B and Sanlioglu S. Abstract. P8-18. 34th FEBS Congress. 4-9 July 2009, Prague, Czech Republic.

39. Pancreatic ductal adenocarcinoma (PDAC) patients reveal elevated TRAIL Death Receptor-4 (DR4) and decoy receptor-2 (DcR2) expression correlated with significant cell death. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS and Sanlioglu S. Abstract. P17. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1104 November 2008.

40. Prolonged normoglycemia in STZ-induced diabetic rats transplanted with adenovirus-mediated human TRAIL gene (Ad5hTRAIL) infected islets. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstract. P59. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1119-1120 November 2008.

41. In vivo imaging to detect the duration of adenovirus mediated EGFP transgene expression in allogeneic islet grafts. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. Abstract. P64. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1121-1122 November 2008.

42. Clinical significance of TRAIL and its receptor expression profiles on CD4+ CD25+ Foxp3+ Tregs and CD8+ CD25+ T cells in patients with rheumatoid arthritis. Bisgin A, Yazisiz V, Ulker M, Terzioglu E and Sanlioglu S. Abstract. P134. XVI Annual Congress of the European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10) 1148-1149 November 2008.

43. Soluble TRAIL concentrations in patients with rheumatoid arthritis. Bisgin A, Yazisiz V, Terzioglu E and Sanlioglu S. Abstract. P135. XVI Annual Congress of the

European Society of Gene Therapy, Brugge, Belgium, Human Gene Therapy. 19:(10)
1149 November 2008.

44. Differential alteration of TRAIL and its receptor expression profiles in patients with pancreatic ductal adenocarcinoma. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. Abstract. 15607. 44th Annual Meeting of American Society of Clinical Oncology. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 15607. Chicago IL USA.

45. High endogenous TRAIL expression level is correlated with increased cell death in human pancreas. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. Abstract. P215. XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.

46. Adenovirus vectors efficiently deliver TRAIL into pancreatic islets without generating cytotoxic effects. Dirice E, Sanlioglu AD, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstract. P214. XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.

47. Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with Rheumatoid Arthritis. Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Terzioglu E and Sanlioglu S. Abstract. P258. XV Annual Congress of the European Society of Gene Therapy, Rotterdam, Netherlands, Human Gene Therapy. 18:(10) 994-1092 October 2007.
48. Expression profile of TRAIL and its receptors in breast cancer patients with invasive ductal carcinoma. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS and Sanlioglu S. Abstract 2136. European Journal of Cancer. 5 (4) 225-226 September 2007.
49. Testing the efficacy of substance P fragments as antitumor agents. Erin E, Korcum AF, Simsek E, Aydemir E, Sanlioglu S. 6th AFMC International Medicinal Chemistry Symposium. Drugs of the Future. Volume 32. Suppl. A. Abstract PA-45. Istanbul, Turkey, July 8-11 2007.
50. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells. Aydin C., Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA and Sanlioglu S. Abstract. P103. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.

51. Small interference RNA technology targeting DcR2 sensitized advanced prostate carcinoma cells to adenovirus delivery of TRAIL. Sanlioglu AD, Koksali IT, Karacay B and Sanlioglu S. Abstract. P140. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
52. TRAIL-R4 (DcR2) receptor gene expression is correlated with high Gleason scores, PSA recurrence, and decreased survival in patients with prostate carcinoma. Koksali IT, Sanlioglu AD, Karacay B, Griffith TS and Sanlioglu S. Abstract. P141. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
53. Novel gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P206. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.
54. Electroporation enhances the first generation adenovirus vector transgene delivery into pancreatic islets. Dirice E, Sanlioglu AD, Omer A, Balci MK and Sanlioglu S. Abstract. P208. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.

55. Upnormal increase in the nuclear NF- κ B activity of the rat cavernosal tissue is correlated with diabetes related erectile dysfunction syndrome. Yoldas B, Usta MF and Sanlioglu S. Abstract. P213. XIV Annual Congress of the European Society of Gene Therapy, Athens, Greece, November 9-12, 2006.

56. A DcR2 siRNA approach defeats TRAIL resistance in lung cancer cells. Aydin C, Sanlioglu AD, Ozbudak O, Dertsiz L, Ozbilim G, Akdis CA and Sanlioglu S. Abstract. P213. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.

57. Differential expression of TRAIL and its receptors in patients with prostate carcinoma. Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, and Sanlioglu S. Abstract. P212. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.

58. Adenovirus delivery of TRAIL effectively destroys synoviocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P214. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.

59. Adenovirus mediated TRAIL gene delivery as a model for the treatment of patients with diabetes. Dirice E, Sanlioglu AD, Omer A, Balci MK, Terzioglu E and Sanlioglu S. Abstract. P482. 31st FEBS Congress, Istanbul, Turkey, June 24-29 2006.

60. Mechanism of TRAIL resistance in breast cancer cells for adenovirus mediated gene delivery. Koksoy S, Sanlioglu AD, Sanlioglu S. Abstract. 141.19. Annual Meeting of the American Association of Immunologists, Boston, MA, May 12-16, 2006.
61. Surface TRAIL decoy receptor-4 expression constitutes a resistance to adenovirus delivery of TRAIL in MCF7 breast cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S. Abstract, PO15. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
62. TRAIL ligand and receptor expressions are differentially upregulated in prostate carcinoma patients: a significant issue for gene therapy of advanced prostate cancer. Sanlioglu AD, Koksal IT, Ciftcioglu A, Bassorgun IC, Baykara M, Luleci G, and Sanlioglu S. Abstract. PO22. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
63. Decoy receptor gene expression as a chief mechanism to govern TRAIL resistance in advanced prostate carcinoma. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, and Sanlioglu S. Abstract. PO23. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
64. Efficient adenovirus mediated TRAIL gene delivery into pancreatic islets as a model for the treatment of patients with type I diabetes. Dirice E, Sanlioglu AD, Omer A,

Balci MK and Sanlioglu S. Abstract. P074. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.

65. Adenovirus delivery of TRAIL effectively destroys synovial fibroblasts of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P075. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.

66. A CTLA-4 exon 1+49 A/A genotype is linked to the clinical progression of systemic lupus erythematosus in patients. Ulker M, Terzioglu E, Yazisiz V and Sanlioglu S. Abstract. P076. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.

67. Testing the efficacy of an adenovirus mediated TRAIL gene delivery for the treatment of patients with osteoarthritis. Bisgin A, Sanlioglu AD, Ulker M, Tuzuner S, Terzioglu E and Sanlioglu S. Abstract. P078. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.

68. A DcR2 siRNA approach overcomes TRAIL resistance in A549 lung cancer cells. Aydin C, Sanlioglu AD, Ozbudak O, Dertsiz L and Sanlioglu S. Abstract. P172. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.

69. Adenovirus mediated NF- κ B inhibiting strategies for the treatment of patients with type I diabetes. Burcak Y and Sanlioglu S. Abstract. P088. 13th Annual Congress of European Society of Gene Therapy, Prag, Czech Republic, 2005.
70. Testing the efficacy of a novel adenovirus mediated TRAIL gene therapy approach for the treatment of patients with Type I Diabetes. Dirice E, Sanlioglu AD, Koksoy S, Balci MK, Omer A and Sanlioglu S. Abstract. P160. Advances in Molecular Medicine, Istanbul, 2005.
71. Adenovirus mediated TRAIL gene delivery as a gene therapy model for patients with advanced prostate carcinoma. Sanlioglu AD, Koksali IT, Karacay B, Baykara M, Luleci G and Sanlioglu S. L14. Advances in Molecular Medicine, Istanbul, 2005.
72. A novel gene therapy model for patients with Rheumatoid Arthritis. Bisgin A, Sanlioglu AD, Ulker M, Dirice E, Tuzuner S, Koksoy S, Terzioglu E and Sanlioglu S. Abstract. P161. Advances in Molecular Medicine, Istanbul, 2005.
73. Adenovirus mediated IKK β expression sensitized advanced prostate carcinoma cells to TRAIL-Mediated apoptosis in spite of decoy receptor gene expression. Sanlioglu AD, Koksali IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. Abstract. P165. Advances in Molecular Medicine, Istanbul, 2005.

74. A novel death ligand mediated gene therapy approach for patients with lung cancer.

Aydin C, Sanlioglu AD, Dirice E, Dertsiz L, Ozbudak O and Sanlioglu S. Abstract.

P162. Advances in Molecular Medicine, Istanbul, 2005.

75. Adenovirus delivery of IKK β KA to liver improves survival in a murine model of

endotoxic shock. Yoldas B, Engelhardt JF and Sanlioglu S. Abstract. P167.

Advances in Molecular Medicine, Istanbul, 2005.

76. Surface TRAIL Receptor-4 expression correlates with TRAIL resistance in breast

cancer cells. Sanlioglu AD, Dirice E, Aydin C, Erin E, Koksoy S and Sanlioglu S.

Abstract. P164. Advances in Molecular Medicine, Istanbul, 2005.

77. Fundamental principals of Tumor Necrosis Factor- α gene therapy approach for

patients with lung carcinoma. AD Sanlioglu, C Aydin, H Bozcuk, E Terzioglu and S

Sanlioglu Abstract. Or4. 12th Annual Congress of European Society of Gene

Therapy, Tampere, Finland 2004

78. Anti HIV drug PDTC genotoxic agents synergistically activate Adeno Associated

Virus Type-2 endocytosis and transduction. AD Sanlioglu, B Karacay, PK Benson,

JF Engelhardt and S Sanlioglu Abstract. P56. 12th Annual Congress of European

Society of Gene Therapy, Tampere, Finland, 2004

79. Advanced prostate cancer cells display differential NF- κ B activation pattern which is the primary determinant of TRAIL resistance. AD Sanlioglu, IT Koksal, M Baykara, G Luleci, B Karacay and S Sanlioglu Abstract, P19. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004

80. Resistance to Adenovirus mediated TRAIL gene therapy in breast cancer cells is eliminated by the expression of dominant negative IKK β . AD Sanlioglu, E Dirice and Salih Sanlioglu. Abstract. P20. 12th Annual Congress of European Society of Gene Therapy Tampere, Finland, 2004

81. Therapeutic effect of recombinant adenovirus mediated TRAIL gene therapy method in Lung Cancer. C Aydin, AD Sanlioglu, E Dirice and Salih Sanlioglu. Abstract. P22. 12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 2004

82. An in vivo model for IKK modulation of adenovirus delivery of TNF- α mediated gene therapy for patients with lung carcinoma. Sanlioglu S. Abstract. P38. British Association for Cancer Research (BACR) Conference on Stem cells and Telomerase. Salamis Bay, NC, 2004

83. Adenovirus mediated NF- κ B inhibiting gene therapy for breaking down TRAIL resistance observed in advanced prostate carcinoma. Sanlioglu AD, Koksali IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. Abstract. P234. 11th Annual Congress of European Society of Gene Therapy, Edinburgh, UK 2003
84. Gene Expression of a Dominant Negative IKK-beta Mutant in the Liver Improves Survival in a Murine Model of Endotoxic Shock. Sanlioglu S, Williams CM, Sanlioglu AD and Engelhardt JF. Abstract. P269. 11th Annual Congress of European Society of Gene Therapy, Edinburgh, UK 2003
85. TRAIL-Mediated Apoptosis of Neuroblastoma cells is Enhanced by Simultaneous Inhibition of the NF- κ B Pathway. Bahri Karacay, Salih Sanlioglu, Thomas S. Griffith, Anthony Sandler, Nicholas J. Pantazis and Daniel J. Bonthius, Neuroscience Meeting, Abstracts, 2003
86. PTEN expression inversely correlates with high Gleason scores and serum PSA levels which are the major prognostic indicators of the advanced prostate carcinoma. Koksali I.T., Dirice E., Yasar D., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. P31. Innovations in the Diagnosis and Treatment of Prostate Cancer, 6th Seminar of the International Cooperative Study of Diagnostic Ultrasound and Prostate Cancer, Antalya-Turkey, 2002

87. PTEN as a diagnostic tool for the prognosis of prostate carcinomas. Dirice E., Koksal I.T., Yasar D., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. International Journal of Cancer, P745 18th UICC International Cancer Congress. Oslo-Norway, 2002
88. Abrogation of PTEN expression is crucial for the progression of bladder carcinomas. Yasar D., Koksal T., Dirice E., Ozes O.N., Baykara M., Luleci G., and Sanlioglu S. Abstract. International Journal of Cancer, P714 18th UICC International Cancer Congress. Oslo-Norway, 2002
89. A new treatment modality for lung cancer; Differential regulation of Rac1 and IKK pathways sensitizes lung cancer cells to TNF mediated apoptosis. Sanlioglu S., Luleci G. and Thomas K.W. Abstract, Journal of Gene Medicine. P149. 9th Annual Meeting of European Society of Gene Therapy, Antalya, Turkey, 2001
90. GPx-1 regulated intracellular hydrogen peroxide level specifically modulates IKK-alpha activity. Li Q, Sanlioglu S, Li SJ, Ritchie T, Oberley L, Engelhardt JF. Molecular Biology of the Cell, 12: 1947 Suppl. S NOV 2001
91. Novel approaches to induce Adeno-associated virus type-2 endocytosis through synergistic activation of Rac1 and PI3K pathways. Sanlioglu S., Benson P., Ritchie T.

and Engelhardt J.F. Abstract 522, Molecular Therapy. 4th Annual Meeting of American Society of Gene Therapy, 2001

92.Regulation of Adeno-Associated Virus Type-2 Endocytosis and Nuclear Trafficking by Rac1/PI3-kinase Pathways. Sanlioglu S., Benson PK. Yang J., Atkinson E.M., Reynolds T. and Engelhardt J.F. Abstract 348, Molecular Therapy. 3rd Annual Meeting of American Society of Gene Therapy, 2000

93.ATM gene defect increases the efficiency of adeno-associated virus transductions. Sanlioglu S and Engelhardt J. Abstract 596, Molecular Therapy. 2nd Annual Meeting of American Society for Gene Therapy, 1999.

94.UV radiation increases the abundance of AAV circular but not replication form intermediates. Sanlioglu S and Engelhardt J. Abstract 227, Pediatric Pulmonology, 1998.

95.UV radiation and reactive oxygen species augment rAAV transduction through NFkB independent pathways. Sanlioglu S and Engelhardt J. Abstract 226, Pediatric Pulmonology, 1998.

96. Effect of ectopic En-2 expression in Purkinje cells on development of the cerebellum.

Sanlioglu S and Oberdick J. Abstract 121.2, Society for Neuroscience, 1996.

97. Activation of a Purkinje cell specific gene by homeobox proteins. Sanlioglu S and

Oberdick J. Abstract 2000. Molecular Biology of the Cell, 1995.



ABSTRACTS and PRESENTATIONS (NATIONAL MEETINGS):

1. Allojenik ve xenojenik pankreatik adacık transplantasyon başarısının in-vivo floresan görüntülemeyle takibi. Kahraman S., Dirice E., Hapil FZ., Ozturk S., Griffith TS., Sanlioglu AD., Sanlioglu S. 46. Ulusal Diyabet Kongresi, Abstrakt SS05, Antalya, 12-16 Mayıs 2010.
2. Non-obese diabetic (NOD) farelerde streptozotosin veya siklofosfamid ile indüklenen diyabette T1D'in moleküler patogenezinin aydınlatılmasına yönelik bulgular. Sanlioglu AD., Kahraman S., Dirice E., Elpek O., Aydın C., Balci MK., Omer A., Sanlioglu S. 46. Ulusal Diyabet Kongresi, Abstrakt SS06, Antalya, 12-16 Mayıs 2010.
3. TRAIL ve reseptörlerinin yassı hücreli larenks ve oral kavite kanserleriyle ilişkisi. Yoldaş B, Ozer C, Ozen O, Canpolat T, Dogan I, Sanlioglu S ve Ozluoglu LN. 31. Ulusal Kulak Burun Bogaz ve Bas ve Boyun Cerrahisi Kongresi. 28 Ekim-1 Kasım 2009. Antalya, Türkiye.

4. Sistemik adenovirus aracılı gen nakli in vivo olarak CCD kameralar ile başarıyla görüntülenebilir. Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Bageci H, Erkilic M, Griffith TS ve Sanlioglu S. S32. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi. 28-31 Ekim 2009. Bodrum, Türkiye.
5. Ex vivo adenovirus aracılı EGFP gen aktarımı yapılan pankreatik adacık ksenotransplantasyon başarısı CCD kamera ile belirlendi. Kahraman S, Dirice E, Sanlioglu AD, Hapil FZ, Balci MK, Omer A, Griffith TD and Sanlioglu S. S39. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi. 28-31 Ekim 2009. Bodrum, Türkiye.
6. Serum sTRAIL konsantrasyonunun romatoid artrit tanısındaki yeri. Bisgin A, Aydın C, Erbasan F, Terzioglu E ve Sanlioglu S. P145. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi. 28-31 Ekim 2009. Bodrum, Türkiye.
7. Tip I diyabette alloimmune mononükleer hücre infiltrasyonun gen tedavisiyle baskılanması fonksiyonel adacık-graft ömrünü uzatır. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstrak. 45. Ulusal Diyabet Kongresi. 20-24 Mayıs 2009, Antalya, Türkiye.

8. Diyabetik farelere sıçan pankreatik adacıklarının ksenotransplantasyonu normoglisemi sağlamaktadır. Kahraman S, Dirice E, Sanlioglu AD, Omer A, Balci MK, Griffith TS and Sanlioglu S. Abstrak. 45. Ulusal Diyabet Kongresi. 20-24 Mayıs 2009, Antalya, Türkiye.
9. BevacizumAb tedavisi uygulanan kolon kanserli hastalarda sTRAIL düzeyinin artışı sağ kalım süresi ile ilişkilidir. Bisgin A, Aydın C, Yalcin AD, Kargı A, Ekinci D, Terzioglu E, Savas B ve Sanlioglu S. Bildiri Ref. No:P410. XVIII. Ulusal Kanser Kongresi. 21-26 Nisan 2009, Antalya, Türkiye.
10. In vivo fluorescent imaging of adenovirus delivery of reporter gene expression for allogeneic islet transplantation. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 11, İstanbul, 29 Mayıs-1 Haziran 2008.
11. Adenovirus-mediated human TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets provides prolonged normoglycemia in STZ-induced diabetic rats. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 10, İstanbul, 29 Mayıs-1 Haziran 2008.

12. The success of rat islet isolation mainly relies on complete pancreas inflation.
Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Balci MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 4, Istanbul, 29 Mayıs-1 Haziran 2008.
13. Gene therapy application scenarios to prolong islet-graft survival in patients with type I diabetes: Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract, Istanbul, 29 Mayıs-1 Haziran 2008.
14. Pancreatic ductal adenocarcinoma (PDAC) patients displayed high levels of TRAIL death receptor-4 (DR4) and decoy receptor-2 (DCR2) expressions in connection with significant amount of cell death. Sanlioglu AD, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 5, Istanbul, 29 Mayıs-1 Haziran 2008.
15. Gene therapy mediated apoptosis inducing approaches employing Ad5hTRAIL and a DCR2 siRNA strategy in lung cancer patients. Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 3, Istanbul, 29 Mayıs-1 Haziran 2008.

16. Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with rheumatoid arthritis. Bisgin A, Sanlioglu AD, Yazisiz V, Terzioglu E, Sanlioglu S. 3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, Abstract No 14, Istanbul, 29 Mayıs-1 Haziran 2008.
17. Pankreatik adacıklarda adenoviral vektor aracili transgen sentez suresinin in vivo olarak CCD kamera ile goruntulenmesi. Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
18. Pankreatik adaciklara adenovirus aracili insan TRAIL geni (Ad5hTRAIL) aktarimi STZ induklemeli diyabetik sicanlarda uzun sureli normoglisemi saglar. Dirice E, Sanlioglu AD, Kahraman S, Omer A, Balci MK, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
19. Tip I diyabet hastalarinda gerceklestirilen adacik naklinde graft sagkalimini uzatabilecek gen tedavi senaryolari: Kahraman S, Dirice E, Sanlioglu AD, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.

20. Pankreatik adacık izolasyon basarisini artirmaya yonelik yapilan deneysel bir calisma: Kahraman S, Dirice E, Sanlioglu AD, Yoldas B, Balci MK, Omer A, Griffith TS and Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
21. Pankreatik duktal adenokarsinomali hastalarda trail olum reseptoru-4 (DR4) ve yalanci reseptor-2'nin (DCR2) ekspresyonlarindaki artis, artan hucre olumleri ile iliskilidir. Sanlioglu AD, Dirice E, Elpek O, Korcum A, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. 44. Ulusal Diyabet Kongresi, Abstract, Antalya, 28 Mayıs-1 Haziran 2008.
22. TRAILING from molecular diagnostics to prostate cancer gene therapy. Sanlioglu AD, Koksali IT, Karacay B, Ciftcioglu MA, Baykara M, Luleci G, Griffith TS and Sanlioglu S. XIX Ulusal Immunoloji Kongresi, Abstract, Antalya, 21-24 Kasım 2007.
23. Yokluğu Tip I diyabetle ilişkilendirilmiş TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, PS54, Antalya, 9-13 Mayıs 2007.

24. Tip I diyabetli hastalarda kullanılacak etkin bir tedavi modelinin geliştirilmesi

maksadıyla pankreatik adacıklara adenovirus aracılı TRAIL geni aktarımı. Dirice E, Sanlioglu AD, Ömer A, Balci MK, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, P551, Antalya, 9-13 Mayıs 2007.

25. Tip I diyabette ölümcül ligant aracılı gen tedavi modelinin moleküler etki mekanizması.

Sanlioglu AD, Dirice E, Ömer A, Terzioğlu E, Sarı R, Balci MK, Griffith TS and Sanlioglu S. 43. Ulusal Diyabet Kongresi, Abstract, Antalya, 9-13 Mayıs 2007.

26. Tip I diyabet gelişiminde rol alan TNF-Related Apoptosis Inducing Ligand (TRAIL)

ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili ve artan apoptozis ile korelasyonu. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Ömer A, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P112, Antalya, 6-9 Eylül 2007.

27. Adenoviral vektörler sitotoksik etki oluşturmadan pankreatik adacıklara etkin TRAIL

gen aktarımı sağlar. Dirice E, Sanlioglu AD, Ömer A, Balci MK, Griffith TS and Sanlioglu S. X. Tıbbi Biyoloji ve Genetik Kongresi, Abstract, P134, Antalya, 6-9 Eylül 2007.

28. Adenovirus aracılı TRAIL transferi osteoartritli hastalardan izole edilmiş normalde

apoptoza dirençli sinovyal fibroblastları yok etti. Bisgin A, Sanlioglu AD, Tuzüner S,

Terzioglu E and Sanlioglu S. X. Tibbi Biyoloji ve Genetik Kongresi, Abstract, P153, Antalya, 6-9 Eylül 2007.

29. Potential therapeutic efficacy of adenovirus delivery of TRAIL for patients with prostate carcinoma. Sanlioglu AD, Koksall IT, Karacay B, Ciftcioglu MA, Baykara M, Luleci G, Griffith TS and Sanlioglu S. X. Tibbi Biyoloji ve Genetik Kongresi, Abstract K11, Antalya, 6-9 Eylül 2007.

30. Adenovirus aracılı ölümcül ligand transferinin gen tedavisindeki yeri. Sanlioglu S. IX. Ulusal Tibbi Biyoloji Kongresi, Abstract K19, Manisa, 2005.

31. İleri evre prostat kansinmada yalancı reseptör gen ekspresyonu TRAIL dirençliliğinin ortaya çıkmasında önemli bir faktördür. Sanlioglu AD, Koksall IT, Karacay B, Baykara M, Luleci G, Griffith TS and Sanlioglu S. IX. Ulusal Tibbi Biyoloji Kongresi, Abstract P12, Manisa, 2005.

32. Adenovirus aracılı TRAIL gen transferinin romatoid artritli hastalıklardaki terapötik etkisi. Bisgin A, Sanlioglu AD, Ulker M, Tuzüner S, Terzioglu E and Sanlioglu S. IX. Ulusal Tibbi Biyoloji Kongresi, Abstract P41, Manisa, 2005.

33. Tip I diyabetli hastalar için geliştirilen pankreatik adacık transplantasyonunda adenovirus aracılı TRAIL gen transferinin etkinliği. Dirice E, Sanlioglu AD, Ömer A,

Balçı MK, and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract P66, Manisa, 2005.

34.DcR2 siRNA yaklaşımı A549 akciğer kanser hücrelerini adenovirus aracılı TRAIL transferine duyarlı kılar. Aydın C, Sanlioglu AD, Özbudak Ö, Dertsiz L and Sanlioglu S. IX. Ulusal Tıbbi Biyoloji Kongresi, Abstract AG05, Manisa, 2005.

35.The implication of adenovirus mediated death ligand gene delivery for human gene therapy. Sanlioglu AD, Koksall IT, Baykara M, Luleci G, and Sanlioglu S. XVIII. Ulusal İmmunoloji Kongresi, Abstract, Antalya, 2005.

36.Current Progress in Cancer Gene Therapy. Sanlioglu S. XIX Ulusal Biyokimya Kongresi, Abstract K05, Antalya, 2005.

37.Hücre içi anti-apoptotik yolun bloke edilmesi meme kanserini adenovirus aracılı TRAIL gen tedavi metoduna karşı duyarlı hale getirdi. Sanlioglu AD, Dirice E, and Sanlioglu S. I. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P127, İstanbul, 2004.

38.Akciğer kanserinde recombinant adenovirus aracılı TRAIL gen tedavi metodunun terapötik etkisi. Aydın C, Sanlioglu AD, Dirice E, and Sanlioglu S. I. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, Abstract P128, İstanbul, 2004.

39. An in vivo model for IKK modulation of adenovirus delivery of TNF-alpha mediated gene therapy for patients with lung carcinoma. Sanlioglu S. I. Ulusal Klinik Pratikde K k H cre ve Gen Tedavisi Kongresi, Abstract P135, İstanbul, 2004.

40. Akcięer kanserinde yeni bir adenovirus aracılı TNF-alpha gen tedavi metodu. Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Abstract, KSB 08, Antalya, 2004.

41. İleri evre prostat kanserinde NFkB yolunun bloke edilmesi TRAIL dirençlilięini kırar. Sanlioglu AD, Koksall IT, Baykara M, Luleci G, Karacay B and Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Abstract, MP 27, Antalya, 2004.

42. Karacięerde adenovirus aracılı dominant negative IKK beta mutandınının gen sentezi endotoksik şoktan hayatta kalma süresini arttırır. Sanlioglu S and Engelhardt JF. VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Abstract, MP 47, Antalya, 2004.

43. İleri evre meme kanserinin adenovirus aracılı TRAIL gen tedavi metoduna duyarlılaştırma yöntemleri. Sanlioglu AD, Dirice E, and Sanlioglu S. VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Abstract, KP 04, Antalya, 2004.

44.PTEN ekspresyon düzeyinin mesane kanseri gelişimindeki rolü. Yasar D, Koksal IT, Dirice E, Özeş ON, Baykara M, Karauzum SB, Luleci G, and Sanlioglu S. XV. Ulusal Kanser Kongresi, Abstract, P558, Antalya, 2003.

45.Prostat kanserli olgularda PTEN ekspresyonunun prognostic değeri. Dirice E Koksal IT, , Yasar D, Özeş ON, Baykara M, Luleci G, and Sanlioglu S. XV. Ulusal Kanser Kongresi, Abstract, P559, Antalya, 2003.

46.Gen tedavisinde güncel gelişmeler. Sanlioglu S and Sanlioglu AD. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract, Adana, 2003.

47.Adenovirus aracılı TRAIL geni aktarımının prostat karsinomanın farklı evreleri üzerindeki etkinliği ve prostat kanserli hastalarda TRAILe olan direnci kırmak için yeni gen tedavi metotlarının geliştirilmesi. Sanlioglu AD, Koksal IT, Baykara M, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract ÖS-3, Adana, 2003.

48.Mesane kanser gelişiminde PTENin prognostik deęerinin belirlenmesi. Yasar D, Koksal IT, Dirice E, Karauzum SB, ifioęlu A, Baykara M, zeş ON, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi. Abstract SS-4, Adana, 2003.

49.PTENin Gleson skoru ve PSAya kıyasla prostat kanserindeki prognostik deęerinin belirlenmesi. Dirice E Koksal IT, , Yasar D, Sanlioglu AD, ifioęlu A, Glkesen KH, zeş ON, Baykara M, Luleci G, and Sanlioglu S. 8. Ulusal Tıbbi Biyoloji Kongresi, Abstract SS-5, Adana, 2003.



AWARDS:

- 2010 Diabetes Mellitus Publication Award, 1st place
- Altan Gunalp Medical Research Award, 1st place 2009
- Altan Gunalp Medical Research Award, 3rd place 2009
- National Head and Neck Surgery Congress, 1st place 2009
- 6th Metabolic syndrome symposium Poster Award 1st place, 2009
- Novartis Diabetes Research Award, 2009
- 11th European Endocrinology Congress Investigator Award, 2009
- Akdeniz University Scientific Achievement Award, 2007
- Altan Gunalp Medical Research Award, 1st place 2007
- 43rd National Diabetes Congress Poster Award. 2nd place, 2007
- European Union Framework Program Project Proposal Submission Encouragement Award, 2005

- Abbott Rheumatoid Arthritis Research Award, 2nd place, 2005
- TUBITAK Investigator Career Project Award, 2004
- Schering-German Urooncology Award, 1st place. 2004. The testing of a novel treatment modality in order to breakdown TRAIL resistance in prostate cancer.
- Schering-German Urooncology Award, 3rd place. 2003. The assessment of PTEN as a prognostic marker in combination with Gleason scoring and serum PSA in order to evaluate the progression of prostate carcinoma.
- Altan Gunalp Medical Research Award, 1st place 2003
- Highest Caliber in Medical Research, University of Iowa, College of Medicine 2000
- National Research Service Award, U.S. National Institute of Health, Bethesda, Maryland 1998
- Excellence in Scientific Presentation, 18th annual meeting of Graduate Student Forum, ICSABER Society of the Ohio State University, Columbus, Ohio
- Excellence in Scientific Presentation, Children's Hospital Research Foundation, The Ohio State University, Columbus, Ohio, 1992



MEMBERSHIP to PROFESSIONAL SOCIETIES:

- Member of the European Society of Gene Therapy 2002 to current
- Member of the American Society of Gene Therapy 1998-2001
- Member of the Society for Neuroscience 1994-1997
- Member of the Turkish Society of Medical Genetics
- Member of the Turkish Society of Medical Biology and Genetics

INTERNATIONAL GRANT REVIEWER EXPERTISE:

- European Union Framework Program 6 (2002-2006)
- American Association for Cancer Research
- International Cancer Technology Transfer Fellowships (ICRETT)
- Translational Cancer Research Fellowships (TCRF)
- Irish Health Research Board Grant Review



REFEREED JOURNALS

- BMC Cancer
- Cancer Biology and Therapy
- Cancer Detection and Prevention
- Cancer Informatics
- Cancer Letters
- Cell Death and Differentiation
- Current Gene Therapy
- Diabetes
- Expert Review of Dermatology
- Future Virology
- Gene Therapy
- Journal of Cell Biology

- Journal of Gene Medicine
- Journal of Pharmacy and Pharmacology
- Journal of Urology
- Nature Clinical Practice Oncology
- Transplant Immunology
- Turkiye Klinikleri Tip Bilimleri Dergisi



TRAINED MEDICAL FELLOWS AND GRADUATE STUDENTS

- Peter K. Benson MD (1999-2001)
- Carl M. Williams MD (1999-2001)
- Ahter Dilsad Sanlioglu PhD (2001-2005)
- Atil Bisgin MD, PhD (2003-2009)
- Ercument Dirice MS (2001-2003) , PhD (2004-2009)
- Burcak Yoldas PhD (2004-2008)
- Duygu Yasar MS (2001-2003)
- Cigdem Aydin MS (2002-2004), PhD (2005-2011)
- Sevim Kahraman MS (2006-2008)
- Fatma Zehra Hapil MS (2010-Pending)